Literature DB >> 19213865

European consensus statement on the terminology used in the management of lupus glomerulonephritis.

C Gordon1, D Jayne, C Pusey, D Adu, Z Amoura, M Aringer, J Ballerin, R Cervera, J Calvo-Alén, C Chizzolini, Jm Dayer, A Doria, F Ferrario, J Floege, L Guillevin, M Haubitz, F Hiepe, F Houssiau, P Lesavre, L Lightstone, Pl Meroni, O Meyer, B Moulin, K O'Reilly, M Praga, H Schulze-Koops, Ra Sinico, Kgc Smith, A Tincani, C Vasconcelos, G Hughes.   

Abstract

Systemic lupus erythematosus (SLE) is a complex, multisystem autoimmune disorder, which often involves referral to multiple medical specialists. Lupus nephritis (LN) occurs in ~35% of adults with SLE and predicts poor survival. There is currently no consensus on how to manage patients with SLE or LN across specialties and across different European countries. The Lupus Nephritis Terminology Advisory Group was formed to address this issue as it impacts upon LN treatment. It has developed consensus statements based on opinions from expert panel meetings with nephrologists, nephropathologists, rheumatologists, clinical immunologists and internal medicine specialists from many European countries, after reviewing current guidelines from the European League Against Rheumatism, the American College of Rheumatology and the participants' experience. In this article, we report consensus statements that were developed in six important areas: classification of patients with LN, how classification affects the selection of treatment options and definitions of induction, response, flare and maintenance. We have also proposed a consensus for the terminology involved in the management of LN that is consistent with clinical opinion gathered from multidisciplinary expert meetings and with existing guidelines. We believe this consensus approach provides agreed expert opinion to clinicians and will form the basis for optimising LN treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19213865     DOI: 10.1177/0961203308100481

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  36 in total

1.  Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.

Authors:  Rina Mina; Emily von Scheven; Stacy P Ardoin; B Anne Eberhard; Marilynn Punaro; Norman Ilowite; Joyce Hsu; Marisa Klein-Gitelman; L Nandini Moorthy; Eyal Muscal; Suhas M Radhakrishna; Linda Wagner-Weiner; Matthew Adams; Peter Blier; Lenore Buckley; Elizabeth Chalom; Gaëlle Chédeville; Andrew Eichenfield; Natalya Fish; Michael Henrickson; Aimee O Hersh; Roger Hollister; Olcay Jones; Lawrence Jung; Deborah Levy; Jorge Lopez-Benitez; Deborah McCurdy; Paivi M Miettunen; Ana I Quintero-del Rio; Deborah Rothman; Ornella Rullo; Natasha Ruth; Laura E Schanberg; Earl Silverman; Nora G Singer; Jennifer Soep; Reema Syed; Larry B Vogler; Ali Yalcindag; Cagri Yildirim-Toruner; Carol A Wallace; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

2.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

3.  The persistent challenge of lupus nephritis.

Authors:  Guido Valesini; Fabrizio Conti
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

4.  ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis.

Authors:  Jung Yoon Pyo; Seung Min Jung; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Rheumatol Int       Date:  2019-02-26       Impact factor: 2.631

5.  A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?

Authors:  Dimitrios T Boumpas; George K Bertsias; James E Balow
Journal:  Ann Rheum Dis       Date:  2010-12       Impact factor: 19.103

6.  Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Kristina Wiers; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Marisa S Klein-Gitelman; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

Review 7.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 8.  [Systemic lupus erythematosus. Target criteria for treatment].

Authors:  T Alexander; R Biesen; A Jacobi; B Hoyer; A Bruns; F Hiepe
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

9.  Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor.

Authors:  Jae-Seung Moon; Diane Da-Hyun Lee; Yong-Beom Park; Sang-Won Lee
Journal:  Clin Rheumatol       Date:  2017-11-08       Impact factor: 2.980

Review 10.  Lupus nephritis: review of the literature.

Authors:  Adeel Zubair; Marianne Frieri
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.